r.rotation.to⌕ Search stocks, people, sectors
Following this device: dark.
Request a free account

Follow the people · Insider

ML

Mark Lappe

Insider · Chief Executive Officer · INBX

Mark Lappe files insider transactions with the SEC as a chief executive officer of Inhibrx. We hold 1 disclosed purchase or sale filed since 21 December 2007, 1 of them in the last 90 days.

  • Files for 3 companiesINBX, INXB, RPRX
  • Disclosed buys and sells1 in all, 1 in the last 90 days
  • Last disclosure8 September 2026

Positions held

3 posts we hold — a term names its own dates; a run of filings only says when they filed
  • Filed 28 December 2020 — 8 September 2026Chief Executive Officer · Inhibrx 40 Form 4 lines · source: SEC Form 4
  • Filed 29 May 2024 — 30 May 2024Chief Executive Officer · Inhibrx Biosciences 4 Form 4 lines · source: SEC Form 4
  • Filed 20 December 2007 — 15 December 200910% owner · Repros Therapeutics 26 Form 4 lines · source: SEC Form 4

Every transaction

70 transactions from SEC Form 4 — one row each, sort any column, open a row for the filing
70 of 70 shown
8 Sep 20268 Sep 2026SEC Form 40 dbought on the open marketInhibrx Biosciences5,895 sharesdown −1.3%down −1.3%
8 Sep 20268 Sep 2026SEC Form 40 dbought on the open marketInhibrx Biosciences6,605 sharesdown −1.3%down −1.3%
8 Sep 20268 Sep 2026SEC Form 40 dbought on the open marketInhibrx Biosciences1,100 sharesdown −1.3%down −1.3%
8 Sep 20268 Sep 2026SEC Form 40 dbought on the open marketInhibrx Biosciences500 sharesdown −1.3%down −1.3%
8 Sep 20268 Sep 2026SEC Form 40 dbought on the open marketInhibrx Biosciences1,219 sharesdown −1.3%down −1.3%
8 Sep 20268 Sep 2026SEC Form 40 dbought on the open marketInhibrx Biosciences9,681 sharesdown −1.3%down −1.3%
16 Sep 202416 Sep 2024SEC Form 40 dbought on the open marketInhibrx Biosciences13,037 sharesup +547.5%up +547.5%
12 Sep 202416 Sep 2024SEC Form 44 dbought on the open marketInhibrx Biosciences26,963 sharesup +648.4%up +547.5%
10 Sep 202410 Sep 2024SEC Form 40 dbought on the open marketInhibrx Biosciences8,500 sharesup +643.5%up +643.5%
9 Sep 202410 Sep 2024SEC Form 41 dbought on the open marketInhibrx Biosciences9,500 sharesup +642.5%up +643.5%
6 Sep 202410 Sep 2024SEC Form 44 dbought on the open marketInhibrx Biosciences26,000 sharesup +649.4%up +643.5%
3 Sep 20243 Sep 2024SEC Form 40 dbought on the open marketInhibrx Biosciences15,288 sharesup +607.6%up +607.6%
3 Sep 20243 Sep 2024SEC Form 40 dbought on the open marketInhibrx Biosciences4,712 sharesup +607.6%up +607.6%
30 Aug 20243 Sep 2024SEC Form 44 dbought on the open marketInhibrx Biosciences10,000 sharesup +675.1%up +607.6%
29 Aug 20243 Sep 2024SEC Form 45 dbought on the open marketInhibrx Biosciences10,000 sharesup +711.4%up +607.6%
21 Aug 202422 Aug 2024SEC Form 41 dbought on the open marketInhibrx Biosciences12,945 sharesup +764.8%up +768.8%
20 Aug 202422 Aug 2024SEC Form 42 dbought on the open marketInhibrx Biosciences27,055 sharesup +774.2%up +768.8%
30 May 202430 May 2024SEC Form 40 dwas grantednot a tradeInhibrx Biosciencesderivative300,000 shares——
30 May 202430 May 2024SEC Form 40 dreturned to the issuernot a tradeInhibrxderivative100,000 sharesup +611.6%up +611.6%
30 May 202430 May 2024SEC Form 40 dreturned to the issuernot a tradeInhibrxderivative145,000 sharesup +611.6%up +611.6%
30 May 202430 May 2024SEC Form 40 dreturned to the issuernot a tradeInhibrx2,486,192 sharesup +611.6%up +611.6%
30 May 202430 May 2024SEC Form 40 dreturned to the issuernot a tradeInhibrx500,000 sharesup +611.6%up +611.6%
30 May 202430 May 2024SEC Form 40 dreturned to the issuernot a tradeInhibrx59,462 sharesup +611.6%up +611.6%
29 May 202430 May 2024SEC Form 41 dwas grantednot a tradeInhibrx Biosciences621,548 shares——
29 May 202430 May 2024SEC Form 41 dwas grantednot a tradeInhibrx Biosciences125,000 shares——
29 May 202430 May 2024SEC Form 41 dwas grantednot a tradeInhibrx Biosciences14,865 shares——
28 Feb 20231 Mar 2023SEC Form 41 dsold on the open marketInhibrx60 shares——
3 Jan 20233 Jan 2023SEC Form 40 dwas grantednot a tradeInhibrxderivative100,000 shares——
19 Dec 202220 Dec 2022SEC Form 41 dsold on the open marketInhibrx25,246 shares——
19 Dec 202220 Dec 2022SEC Form 41 dsold on the open marketInhibrx754 shares——
17 Nov 202218 Nov 2022SEC Form 41 dsold on the open marketInhibrx6,959 shares——
17 Nov 202218 Nov 2022SEC Form 41 dsold on the open marketInhibrx4,106 shares——
17 Nov 202218 Nov 2022SEC Form 41 dsold on the open marketInhibrx4,333 shares——
17 Nov 202218 Nov 2022SEC Form 41 dsold on the open marketInhibrx1,767 shares——
17 Nov 202218 Nov 2022SEC Form 41 dsold on the open marketInhibrx6,773 shares——
17 Nov 202218 Nov 2022SEC Form 41 dsold on the open marketInhibrx912 shares——
17 Nov 202218 Nov 2022SEC Form 41 dsold on the open marketInhibrx1,150 shares——
17 Oct 202218 Oct 2022SEC Form 41 dsold on the open marketInhibrx8,981 shares——
17 Oct 202218 Oct 2022SEC Form 41 dsold on the open marketInhibrx14,006 shares——
17 Oct 202218 Oct 2022SEC Form 41 dsold on the open marketInhibrx2,892 shares——
17 Oct 202218 Oct 2022SEC Form 41 dsold on the open marketInhibrx121 shares——
15 Jan 202119 Jan 2021SEC Form 44 dwas grantednot a tradeInhibrxderivative145,000 shares——
28 Dec 202019 Jan 2021SEC Form 422 dgave awaynot a tradeInhibrx500,000 shares——
28 Dec 202019 Jan 2021SEC Form 422 dgave awaynot a tradeInhibrx500,000 shares——
15 Dec 200915 Dec 2009SEC Form 40 dsold on the open marketRepros Therapeutics181,700 shares——
14 Dec 200915 Dec 2009SEC Form 41 dsold on the open marketRepros Therapeutics77,900 shares——
11 Dec 200915 Dec 2009SEC Form 44 dsold on the open marketRepros Therapeutics126,500 shares——
20 May 200922 May 2009SEC Form 42 dwas grantednot a tradeRepros Therapeuticsderivative5,000 shares——
31 Oct 20084 Nov 2008SEC Form 44 dbought on the open marketRepros Therapeutics11,300 shares——
29 Oct 200830 Oct 2008SEC Form 41 dbought on the open marketRepros Therapeutics24,400 shares——
28 Oct 200830 Oct 2008SEC Form 42 dbought on the open marketRepros Therapeutics9,892 shares——
27 Oct 200827 Oct 2008SEC Form 40 dbought on the open marketRepros Therapeutics14,825 shares——
24 Oct 200827 Oct 2008SEC Form 43 dbought on the open marketRepros Therapeutics30,000 shares——
23 Oct 200827 Oct 2008SEC Form 44 dbought on the open marketRepros Therapeutics17,309 shares——
17 Oct 200821 Oct 2008SEC Form 44 dbought on the open marketRepros Therapeutics30,000 shares——
13 Oct 200814 Oct 2008SEC Form 41 dbought on the open marketRepros Therapeutics15,000 shares——
10 Oct 200814 Oct 2008SEC Form 44 dbought on the open marketRepros Therapeutics15,300 shares——
2 Oct 20086 Oct 2008SEC Form 44 dbought on the open marketRepros Therapeutics1,846,154 shares——
29 Sep 20086 Oct 2008SEC Form 47 dwas grantednot a tradeRepros Therapeuticsderivative40,000 shares——
29 Sep 20081 Oct 2008SEC Form 42 dwas grantednot a tradeRepros Therapeuticsderivative40,000 shares——
27 Mar 20083 Jul 2008SEC Form 498 dsold on the open marketRepros Therapeutics55,800 shares——
26 Mar 20083 Jul 2008SEC Form 499 dsold on the open marketRepros Therapeutics10,000 shares——
25 Mar 20083 Jul 2008SEC Form 4100 dsold on the open marketRepros Therapeutics60,000 shares——
24 Mar 20083 Jul 2008SEC Form 4101 dsold on the open marketRepros Therapeutics50,000 shares——
20 Mar 20083 Jul 2008SEC Form 4105 dsold on the open marketRepros Therapeutics34,000 shares——
18 Mar 20083 Jul 2008SEC Form 4107 dsold on the open marketRepros Therapeutics10,600 shares——
17 Mar 20083 Jul 2008SEC Form 4108 dsold on the open marketRepros Therapeutics55,357 shares——
14 Mar 20083 Jul 2008SEC Form 4111 dsold on the open marketRepros Therapeutics26,300 shares——
21 Dec 200721 Dec 2007SEC Form 40 dbought on the open marketRepros Therapeutics40,000 shares——
20 Dec 200721 Dec 2007SEC Form 41 dbought on the open marketRepros Therapeutics60,000 shares——

Both percentages are the stock’s move, not Mark Lappe’s return: a disclosure gives a band, never an amount, so nobody can say how much was bought or what it made. They run to the last close we hold — 9 Sep 2026, except where a name has since delisted, when the row names its own last session. We publish no close, no volume and no dollar figure behind them. 22 of the 70 rows shown carry a percentage; the rest are dashes with the reason on the row.

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.

Some filings reach us as photographs of paper rather than as a form we can read as text. Those are shown here only once they have been read and checked, so this page can hold fewer lines than the filings behind it contain. The link on every row opens the original document, which is always the full record.